-
Author
Cengiz, Derya 1 Dobelmann, Vera 1 Gerdes, Norbert 1 Hartung, Hans-Peter 1 Herrmann, Alexander 1 Hu, Hao 1 Huntemann, Niklas 1 Kelm, Malte 1 Koch-Hölsken, Kathrin 1 Meuth, Sven G 1 Mourikis, Philipp 1 Nelke, Christopher 1 Polzin, Amin 1 Ruck, Tobias 1 Räuber, Saskia 1 Schroeter, Christina B 1 Theissen, Lukas 1
- Workplace
- Format
- Publication type
- Check Tag
- Category
- Language
- Country
- Journal/source
- Accessibility
- Owner
-
Author
Cengiz, Derya 1 Dobelmann, Vera 1 Gerdes, Norbert 1 Hartung, Hans-Peter 1 Herrmann, Alexander 1 Hu, Hao 1 Huntemann, Niklas 1 Kelm, Malte 1 Koch-Hölsken, Kathrin 1 Meuth, Sven G 1 Mourikis, Philipp 1 Nelke, Christopher 1 Polzin, Amin 1 Ruck, Tobias 1 Räuber, Saskia 1 Schroeter, Christina B 1 Theissen, Lukas 1
- Workplace
- Format
- Publication type
- Check Tag
- Category
- Language
- Country
- Journal/source
- Accessibility
- Owner
E-resources NLK Online Full text
Directory of Open Access Journals from 2012Free Medical Journals from 2012
PubMed Central from 2012
Europe PubMed Central from 2012
ProQuest Central from 2012-03-01
Open Access Digital Library from 2012-01-01
Open Access Digital Library from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources from 2012
PubMed
38534352
DOI
10.3390/cells13060508
Knihovny.cz E-resources
Myasthenia gravis (MG) is a prototypical autoimmune disease of the neuromuscular junction (NMJ). The study of the underlying pathophysiology has provided novel insights into the interplay of autoantibodies and complement-mediated tissue damage. Experimental autoimmune myasthenia gravis (EAMG) emerged as a valuable animal model, designed to gain further insight and to test novel therapeutic approaches for MG. However, the availability of native acetylcholine receptor (AChR) protein is limited favouring the use of recombinant proteins. To provide a simplified platform for the study of MG, we established a model of EAMG using a recombinant protein containing the immunogenic sequence of AChR in mice. This model recapitulates key features of EAMG, including fatigable muscle weakness, the presence of anti-AChR-antibodies, and engagement of the NMJ by complement and a reduced NMJ density. Further characterization of this model demonstrated a prominent B cell immunopathology supported by T follicular helper cells. Taken together, the herein-presented EAMG model may be a valuable tool for the study of MG pathophysiology and the pre-clinical testing of therapeutic applications.
- MeSH
- Autoantibodies MeSH
- Myasthenia Gravis, Autoimmune, Experimental * drug therapy metabolism MeSH
- Immunization MeSH
- Complement System Proteins MeSH
- Mice MeSH
- Neuromuscular Junction pathology MeSH
- Receptors, Cholinergic * MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Share
Document title
The link will be redirected to the address of the production version after the testing phase.